[Form 4] WEST PHARMACEUTICAL SERVICES INC Insider Trading Activity

Rhea-AI Filing Summary

Janet Brutschea Haugen, a director of West Pharmaceutical Services, Inc. (WST), reported transactions dated 09/30/2025. The Form 4 discloses a disposition of 1,319.348 shares of Common Stock and the acquisition of 48 Phantom Stock Units on the same date. The filing shows 162.161 shares reported as beneficially owned following the reported derivative transaction. Footnotes state the 1,071 restricted stock units and dividend equivalents underlying part of the position will vest in full at the next annual shareholder meeting and be distributable under the Deferred Compensation Plan for Outside Directors, and that phantom stock units are settled by delivery of shares upon the reporting person’s termination as a director. The form is signed by an agent on behalf of Ms. Haugen on 10/02/2025.

Positive

• Director compensation tied to alignment: Restricted stock units and phantom units indicate continued alignment of Ms. Haugen’s incentives with shareholders.
• Clear vesting and settlement terms disclosed: Footnotes specify vesting at the next annual meeting for RSUs and settlement-on-termination for phantom units.

Negative

• None.

Insights

Securities Analyst

TL;DR: Routine director compensation movements: a reported disposition and grant tied to deferred compensation and phantom units.

The Form 4 shows a disposition of 1,319.348 common shares and an award of 48 phantom stock units on 09/30/2025. Footnotes clarify that 1,071 restricted stock units plus dividend equivalents will vest at the next annual meeting and are payable under the outside directors' deferred compensation plan, and that phantom units convert to shares upon termination. These items are consistent with customary director compensation mechanics rather than an operational signal about the company. No cash proceeds, sale price, or reason for the disposition beyond the codes provided are included in the filing.

Corporate Governance Expert

TL;DR: Director-level equity changes reflect standard deferred compensation and termination-settled phantom units.

The filing documents compensatory equity arrangements: restricted stock units that vest at the next annual meeting and phantom stock units that settle in shares upon director termination. Such structures are typical for outside directors to defer income and align incentives with shareholders. The Form 4 does not provide context such as total outstanding director holdings before these entries beyond the post-transaction beneficial ownership figure of 162.161 shares, so governance implications are limited to confirming these standard arrangements exist for Ms. Haugen.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

1. Name and Address of Reporting Person^*

HAUGEN JANET BRUTSCHEA

(Last) (First) (Middle)

530 HERMAN O. WEST DRIVE

(Street)

EXTON PA 19341

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
WEST PHARMACEUTICAL SERVICES INC [ WST ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
09/30/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock								1,319.348(1)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Phantom Stock Unit	(2)	09/30/2025		A		48		(2)	(2)	Common Stock	48	$262.33	162.161	D

Explanation of Responses:

1. Reflects 1,071 shares of restricted stock units and dividend equivalents that will vest in full on the date of the next annual shareholder meeting and will be distributable under the terms of the Deferred Compensation Plan for Outside Directors.

2. Awards of Phantom stock units are to be settled by delivery of shares of stock upon the reporting person's termination as a director.

	/s/ Louis Lalli, as an agent for Janet Haugen	10/02/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What transactions did Janet Haugen report on Form 4 for WST?

The Form 4 reports a disposition of 1,319.348 common shares and the acquisition of 48 phantom stock units on 09/30/2025.

How many shares did Janet Haugen beneficially own after the reported transactions?

The filing shows 162.161 shares beneficially owned following the reported derivative transaction.

What do the footnotes say about the restricted stock units?

Footnote 1 states that 1,071 restricted stock units and dividend equivalents will vest in full at the next annual shareholder meeting and will be distributable under the Deferred Compensation Plan for Outside Directors.

When do the phantom stock units settle into shares?

The filing states phantom stock units are to be settled by delivery of shares upon the reporting person’s termination as a director.

Who signed the Form 4 and when was it signed?

The Form 4 is signed by Louis Lalli as an agent for Janet Haugen with a signature date of 10/02/2025.